tbuckley/cabot-search huggingface dataset:
P3.01-109 Real-World Patient-Reported Outcome Assessment of Patients with Metastatic Non-Small Cell Lung Cancer
Authors: L. Williams, S. Dibaj, S. Chandwani, V. Vaghani, Q. Shi, M. Hirschmann, L.L. Landry, E. Roarty, J. Zhang, W. Rinsurnogkawong, J. Lewis, T. Burke, C. Cleeland, J. Lee, J.A. Roth, S. Swisher, J. Heymach, G. Simon
Journal: Journal of Thoracic Oncology (2018)
Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)
Authors: J. Martin-Liberal, F. Pagliuca, C. Hierro, C. Viaplana, E. Muñoz Couselo, J. Capdevila, I. Matos, L. Fariñas Madrid, E. Zamora, I. Braña Garcia, E. Elez Fernandez, M. Ochoa De Olza Amat, A. Azaro, M. Alsina, M. Vieito Villar, R. Fasani, J. Tabernero, E. Garralda, R. Dienstmann, P.G. Nuciforo
Journal: Annals of Oncology (2018)
Clinical factors are unable to accurately predict the absence of benefit of surgery in patients operated for resection of colorectal liver metastasis
Authors: A. Bohlok, H. Tessely, E. Naets, F. Bouazza, D. Germanova, J.L. Van Laethem, A. Hendlisz, V. Lucidi, V. Donckier
Journal: Annals of Oncology (2018)
Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: A positive prognostic factor for survival?
Authors: I. Prediletto, E. Vasile, R. Bruno, E. Macerola, G. Pasquini, G. Fontanini, A. Falcone
Journal: Annals of Oncology (2018)
Indicators of non-participation in cervical cancer screening: Results from the EDIFICE 6 survey
Authors: T. de La Motte Rouge, S. Couraud, F. Eisinger, M. Roupret, L. Brignoli-Guibaudet, C. Lhomel, L. Greillier, J. Viguier, J.F. Morère
Journal: Annals of Oncology (2018)
A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention
Authors: George Thanassoulis, Allan D. Sniderman, Michael J. Pencina
Journal: JAMA Cardiology (2018)

A 10-year benefit-based approach to statin therapy in primary prevention includes younger individuals with higher low-density lipoprotein cholesterol (LDL-C) and prevents more cardiovascular events than a risk-based approach. However, a 10-year treatment duration likely underestimates the expected benefits of statins.To model the impact of a 30-year benefit approach to select individuals for statin therapy.This cross-sectional analysis of the National Health and Nutrition Survey (NHANES) data set included samples of the US population from the 2009-2010, 2011-2012, and 2013-2014 data collection cycles. Individuals between 40 to 60 years old who did not have atherosclerotic cardiovascular disease, diabetes, or LDL-C levels greater than 190 mg/dL and who were not taking statins were included. Data analysis took place from November 2017 to August 2018.We calculated 10-year risk of atherosclerotic cardiovascular disease and 10-year and 30-year absolute risk reduction (10-year ARR and 30-year ARR) of atherosclerotic cardiovascular disease for each individual.Number of individuals meeting eligibility for statins based on 10-year (atherosclerotic) cardiovascular disease risk, 10-year ARR, or 30-year ARR.A total of 1688 individuals were included, representing 56.6 million US individuals. Statin eligibility based on 7.5% CVR10 was 9.5%; based on 2.3% 10-year ARR, 13.0%, and based on 15% 30-year ARR, 17.5%. The 10-year risk, 10-year benefit, and 30-year benefit approaches all led to similar acceptable mean absolute risk reductions at 30 years, with the benefit-based approaches better able to avoid treatment of individuals with low expected benefit. Individuals who met statin eligibility based solely on the 30-year ARR threshold of 15% or greater were younger (mean age, 50 [95% CI, 48-52] years) and more likely to be women (43% [95% CI, 26%-59%]) than those recommended with a 10-year ARR threshold of 2.3% or greater (mean age, 56 [95% CI, 54-57] years; 22% [95% CI, 10%-34%] women). This group also had lower 10-year risk (mean risk, 4.7% [95% CI, 4.4%-5.1%]) and higher LDL-C levels (mean level, 149 mg/dL [95% CI, 142-155 mg/dL]) than those recommended with a 10-year ARR threshold of 2.3% or greater (mean risk, 9.3% [95% CI, 8.3%-10.2%]; mean LDL-C levels, 110 [103-118] mg/dL). Preventable atherosclerotic cardiovascular disease events in 10 and 30 years were highest using the 30-year benefit approach (296 000 at 10 years and 2.03 million at 30 years) and lowest based on 10-year risk (204 000 at 10 years and 1.18 million at 30 years).A long-term benefit approach to statin eligibility identifies nearly 1 in 6 individuals as having a high degree of expected long-term benefit of statins, with a number needed to treat of less than 7. This approach identifies younger individuals with higher LDL-C levels who would not be currently recommended for treatment and may provide a more optimal approach for determining statin eligibility in primary prevention.
Withholding Anti-EGFR: Impact on outcome of RAS wild-type metastatic colorectal tumours (WAIT OR ACT): A multicentric AGEO study
Authors: L.-J. Palmieri, L. Mineur, D. Tougeron, B.J.-C. Rousseau, V. Granger, J.-M. Gornet, D. Smith, A. Lievre, M.P. Galais, S. Racine Doat, S. Pernot, A.L. Bignon Bretagne, J.-P. Metges, N. Baba-Hamed, M. Hassine, S. Obled, C. Vitellius, O. Bouche, D. Vernerey, R. Coriat
Journal: Annals of Oncology (2018)
Abstract 18492: Phase Analysis Detects Human Atrial Fibrillation Sources While Classical Activation Mapping May Not: Reconciling Classical and Computational Mapping
Authors: Junaid A Zaman, Gautam G Lalani, Tina Baykaner, Shirley Park, David E Krummen, Paul J Wang, Sanjiv M Narayan
Journal: Circulation (2015)

Introduction: The mechanisms maintaining human persistent AF are elusive. It is striking how most optical mapping studies in animal and recently human AF show rotors and focal sources, while most classical activation mapping studies of electrograms do not. We tested the hypothesis that sites in human persistent AF showing rotors by phase analysis may, due to precession (‘wobble’) and fibrillatory collision, rarely reveal sources in activation maps. Methods: We studied 25 patients with persistent AF (LA 47 mm, CHADS2=1.9), in whom phase-mapping of electrograms from 64 pole baskets revealed rotors/focal sources where ablation terminated AF. Electrograms (fig A) were annotated (Matlab) using minimum dV/dt (unipoles, fig B) and peak amplitude criteria (bipoles) to create contours (isochrones), that were classified into a) complete, b) partial or c) unresolvable sources. Results: In each case, ablation at phase-identified rotors/sources (4.0±5.7 mins) terminated persistent AF to sinus rhythm (fig C, 64%) or atrial tachycardia. Notably, isochrones detected sources in only 5/25 (20%) of cases (fig D), more easily in unipolar than bipolar signals. Isochrones revealed partial sources in 11 (44%) and were unresolvable in 9 (36%). Source detection in classical maps was obscured by low signal: noise, varying sequence (rotor precession), or electrode noise that phase analysis resolved by analyzing neighboring sites (fig E). The figure summarizes these steps for a case with perfect agreement between activation and phase maps. Conclusions: Rotors and focal sources for human persistent AF detected by phase analysis were mostly undetected in activation maps, due to rotor precession and fibrillatory conduction. These data may inform approaches to revise classical criteria to better map AF.
P1.01-22 Effect of Basal Lymphopenia on Outcome of Non Small Cell Lung Cancer Patients Treated with Immunotherapy
Authors: G. Galli, M. Poggi, G. Fucà, M. Imbimbo, G. Lo Russo, C. Proto, D. Signorelli, M. Ganzinelli, N. Zilembo, F. De Braud, M. Garassino, M. Vitali
Journal: Journal of Thoracic Oncology (2018)
Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) vs. EZ alone in metastatic castration refractory prostate cancer (mCRPC)
Authors: B.L. Maughan, A. Hahn, J. Hoffman, K. Morton, S. Gupta, J. Batten, J. Thorley, J. Hawks, G. Nachaegari, R. Nussenzveig, K. Boucher, N. Agarwal
Journal: Annals of Oncology (2018)
A real world study of apatinib treatment in gastric cancer: Current status and clinical benefit
Authors: G. Sun, D. Li, Z. Ning, Y. He, J. Chang, F. Zhang, C. Jiang, Y. Cheng, L. Xia, B. Hu, C. Yu, Z. Wang, D. Wang, G. Wang, Y. Zhao, J. Wang, H. Liang, M. Xiong, W. Peng, H. Qian
Journal: Annals of Oncology (2018)
P2.09-23 A Combination of Podoplanin and E-Cadherin Expression in Lung SqCC may be a Poor Prognostic Indicator: A Propensity Score-Matched Analysis.
Authors: R. Miyata, T. Menju, M. Noguchi, H. Ishikawa, S. Nishikawa, K. Takahashi, M. Hamaji, D. Nakajima, A. Ohsumi, T. Chen-Yoshikawa, T. Sato, M. Sonobe, H. Date
Journal: Journal of Thoracic Oncology (2018)
Yap is required for scar formation but not myocyte proliferation during heart regeneration in zebrafish
Authors: Michael A Flinn, Brooke E Jeffery, Caitlin C O’Meara, Brian A Link
Journal: Cardiovascular Research (2018)

Abstract Aims The Hippo signalling pathway regulates multiple cellular processes during organ development and maintenance by modulating activity of the transcriptional cofactor Yap. Core components of this pathway are required for neonatal mouse heart regeneration, however, investigations to date have typically focused on expression and activity in cardiomyocytes. Due to the regenerative capacity of zebrafish and the fact that global loss of Yap is not fully embryonic lethal in zebrafish, we leveraged a yap null mutant to investigate the impact of constitutive Yap deletion during zebrafish heart regeneration. Methods and results Following cryoinjury in adult hearts, myocyte proliferation was not decreased in yap mutants, contrary to expectations based on mouse data. Experiments in larval zebrafish (Danio rerio) revealed that deletion of either Yap or Taz had a modest effect on heart growth, reducing gross organ size, while their combined deletion was synergistic; thus, Yap and Taz share some overlapping roles in zebrafish heart development. Surprisingly, adult yap mutants exhibited decreased collagen composition at 7 days post-injury, suggesting a critical role for Yap in scar formation during heart regeneration. siRNA-mediated Yap knockdown in primary rat (Rattus norvegicus) cardiac cells revealed a fibroblast-specific role for Yap in controlling the expression of cytoskeletal and myofibroblast activation genes, as well as pro-inflammatory cyto/chemokines. Corroborating these RNAseq data, we observed increased macrophage infiltration in the scars of yap mutants at 7 days post-injury. Conclusion These results suggest that Yap deletion has minimal effect on myocyte proliferation in adults, but significantly influences scar formation and immune cell infiltration during zebrafish heart regeneration. Collectively, these data suggest an unexpected role for Yap in matrix formation and macrophage recruitment during heart regeneration.
P1.09-08 Integrating NGS Information for Staging Multiple Lung Adenocarcinoma: A McGill University Health Centre Retrospective Study
Authors: A. Baig, J. Spicer, P. Fiset, H. Wang, S. Owen, R. Fraser, L. Ferri, C. Sirois, L.V. Kempen, G. Chong, A. Spatz, S. Camilleri-Broët
Journal: Journal of Thoracic Oncology (2018)
P1.11-14 Radiological Pleura-Tumor Proximity in Pure-Solid Clinical Stage I Lung Cancer: Its Influence on Lymph Node Metastasis and Recurrence
Authors: T. Tanaka, K. Ueda, J. Murakami, T. Nakamura, S. Yoshimine, K. Hamano
Journal: Journal of Thoracic Oncology (2018)
The role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome
Authors: G. Orsi, K. Andrikou, F. Bergamo, F. Nappo, C. Manai, A. Passardi, M. Puzzoni, S. Vallarelli, M. Libertini, M.L. Riggi, G. Pugliese, A. Zaniboni, M. Schirripa, L. Procaccio, N. Silvestris, M. Scartozzi, A. Casadei Gardini, V. Zagonel, S. Cascinu
Journal: Annals of Oncology (2018)
Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German registry CRISP (AIO-TRK-0315)
Authors: F. Griesinger, W.E.E. Eberhardt, A. Nusch, M. Reiser, C. Bernhardt, N. Marschner, M. Jaenicke, A. Fleitz, L. Spring, J. Sahlmann, A. Karatas, A. Hipper, W. Weichert, A. Rittmeyer, H. Bischoff, C. Waller, M. Thomas
Journal: Annals of Oncology (2018)
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection
Authors: Elisabetta Degasperi, Roberta D’Ambrosio, Massimo Iavarone, Angelo Sangiovanni, Alessio Aghemo, Roberta Soffredini, Marta Borghi, Giovanna Lunghi, Massimo Colombo, Pietro Lampertico
Journal: Clinical Gastroenterology and Hepatology (2018)
P2.06-33 Heterogeneity in Care Pathways for Patients with Malignant Pleural Mesothelioma Presenting at a Quaternary Thoracic Oncology Center in Quebec
Authors: R. Hamed, A. Siblini, D. Thomas, J. Breau, E. Lee, S. Camilleri-Broët, P. Fiset, L. Ofiara, S. Beaudoin, C. Pepe, B. Abdulkarim, N. Kopek, H. Bhanabhai, C. Sirois, L. Ferri, D. Mulder, J. Spicer
Journal: Journal of Thoracic Oncology (2018)
A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumours using intralesional rose bengal disodium
Authors: T.J. Price, G. Cehic, I. Kirkwood, G. Maddern, E.A. Wachter, D. Sarson, R. Sebben, L. Leopardi, J. Reid, S.J. Neuhaus
Journal: Annals of Oncology (2018)
The prognostic value of early tumor response in metastatic nasopharyngeal carcinoma patients treated with first-line chemotherapy
Authors: W.-X. Xia, L. Guoying, X. Lv, S.-H. Lv, X.-J. Huang, W.-Z. Qiu, H. Liang, W.-Z. Li, K.-Y. Liu, Y.-H. Yu, Y.-Q. Xiang, X. Guo
Journal: Annals of Oncology (2018)
OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)
Authors: C.U. Blank, E.A. Rozeman, A.M. Menzies, B.A. van de Wiel, C. Adhikari, K. Sikorska, O. Krijgsman, H. Eriksson, C. Bierman, L. Grijpink-Ongering, M. Gonzalez, A. Broeks, A.D. Guminski, A.J. Spillane, W.M.C. Klop, R.P.M. Saw, R.A. Scolyer, A.C.J. van Akkooi, J. Hansson, G.V. Long
Journal: Annals of Oncology (2018)
Abstract 17021: Association Between Regulatory Review Times and Adverse Event Reports in New Cardiovascular Devices
Authors: Ariel D Stern, Daniel B Kramer, Melissa D Ouellet, Aaron S Kesselheim
Journal: Circulation (2015)

Introduction: The Food and Drug Administration (FDA) approves new high-risk medical devices after reviews of safety and effectiveness data gathered in clinical trials. Some have advocated for shorter review times to encourage innovation. We evaluated whether regulatory review time and product novelty predict adverse events involving high-risk cardiovascular devices. Methods: All high-risk cardiovascular devices approved between 2000-2009, grouped by FDA-assigned product codes were linked to regulatory review data and adverse events reported in the FDA’s Manufacturer and User Facility Device Experience database over the four years following FDA approval. Adverse events were classified according to severity, and linear probability / logistic regression models evaluated whether regulatory review times or product novelty predicted adverse event reporting. Results: Regulatory review times for 106 devices averaged 14.6 (SD: 9.77) months. Only 48/106 (45%) of devices in 28 product codes had at least 1 reported adverse event (mean: 182, range: 1-2706), yielding a total of 8,721 adverse event reports. Shorter regulatory review times were associated with a higher probability of any adverse event, as well as a higher probability of patient injury/death: a one standard deviation decrease in regulatory review time was associated with a 13.7% absolute/30.4% relative increase in risk of any adverse event reporting (95% CI: 6.8-20.5, p&lt;0.001), a 9.8% absolute/39.1% relative increase in absolute risk of adverse events involving serious injury or death (95% CI: 2.0-17.6, p=0.02), and a 9.8% absolute/39.1% relative increase in probability of being in the top quartile of the count of total adverse events involving injury or death (95% CI: 2.0-18.6, p=0.02). Controlling for review time, novelty of a product was not predictive of the presence or frequency of adverse event reports. Conclusion: High-risk cardiovascular devices with shorter FDA reviews were associated with a higher probability of any reported adverse events, of events involving serious injury or death, and were more likely to be among those with the highest number of adverse event reports of injury or death. These data should inform current proposals aimed at expediting the review of high-risk devices.
MA05.07 Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial
Authors: J. Nyman, S. Bergström, H. Björkestrand, A. Svärd, S. Ekman, E. Lundin, E. Holmberg, M. Johansson, S. Friesland, A. Hallqvist
Journal: Journal of Thoracic Oncology (2018)
Abstract 13457: ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latino Based on fFndings From the HCHS-SOL
Authors: Waqas Qureshi, Robert C Kaplan, Katrina Swett, Gregory Burke, Martha Davilgus, Molly Jung, Gregory A Talavera, Diana A Chirinos, Samantha A Reina, Sonia Davis, Carlos Rodriguez
Journal: Circulation (2015)

Introduction: Hispanic/Latinos are the largest ethnic minority in United States with significant cultural and racial heterogeneity. The recent cholesterol treatment guidelines are mainly based on estimates from non-Hispanic white and black cohorts. Aim: To estimate the proportion of US Hispanic adults potentially affected by recent changes in recommendations for statin therapy eligibility under the 3rd National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP III) and the new 2013 ACC/AHA cholesterol treatment guidelines. Methods: HCHS/SOL is a large multi-center study of Hispanics/Latinos in US communities (Bronx, NY; Chicago, IL; Miami, FL; and San Diego, CA) (n=16,415; mean age 41 years, 40% males) . We evaluated weighted prevalence of statin-treated individuals and the proportion of target population that met the eligibility criteria for statin therapy under NCEP/ATP III versus 2013 ACC/AHA cholesterol treatment guidelines. Results: A total of 1,716 (10.4%) were treated with statins in HCHS/SOL cohort. However, 3,366 (20.5%) and 5,268 (32.1%) were eligible for statin therapy under NCEP/ATP III and 2013 ACC/AHA guidelines respectively. The proportion of statin-eligible adults increased primarily among older adults from 44% to 87% and males from 19% to 39% under NCEP/ATP III guidelines and 2013 ACC/AHA guidelines respectively (Figure 1). There was also an increase in eligibility for statin therapy in middle aged adults (44% to 65%). Conclusions: Regardless of the definition for statin eligibility, Hispanics are grossly undertreated (only half and only a third of those statin-eligible under the ATP III or the new ACC/AHA guidelines respectively are receiving treatment). The eligibility of statin therapy almost doubles consistently across all Hispanic/Latinos subgroups of under the new 2013 ACC/AHA guidelines.
Alterations in peripheral T cell subsets, T cell activation markers and immune checkpoint molecules in advanced pancreatic cancer patients receiving FOLFIRINOX or gemcitabine + nab-paclitaxel
Authors: L.E. Sams, S. Kruger, V. Heinemann, D. Bararia, S. Haebe, S. Alig, B. Westphalen, M. Haas, T. Kirchner, S. Ormanns, S. Endres, O. Weigert, M. von Bergwelt-Baildon, S. Kobold, F. Rataj, S. Boeck
Journal: Annals of Oncology (2018)
MA19.05 Difference of Tumor Mutational Burden Is Associated with Distinct Immune Microenviroment in the T Cell-Inflamed Lung Adenocarcinoma
Authors: T. Karasaki, K. Kitano, K. Nagayama, J. Nitadori, M. Sato, M. Anraku, K. Kakimi, J. Nakajima
Journal: Journal of Thoracic Oncology (2018)
A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD)
Authors: I.C. Glitza, M.L. Rohlfs, M. Iqbal, J. Richard, E. Burton, S. Duncan, C. Brown, J. Anderson, P. Hwu, W.-J. Hwu, M. Wong, C. Yee, S. Patel, S. Woodman, R. Amaria, A. Diab, H. Tawbi, M. Davies
Journal: Annals of Oncology (2018)
Dose modification and therapy interruption due to adverse events in treatment with anlotinib for refractory advanced NSCLC: Data from ALTER0303
Authors: L. Zhang, X. Si, H. Wang, X. Zhang, M. Wang, B. Han, K. Li, Q. Wang, J. Shi, Z. Wang, Y. Cheng, J. He, Y. Shi, W. Chen, X. Wang, Y. Luo, K. Nan, F. Jin, B. Li, Y. Chen
Journal: Annals of Oncology (2018)
P2.01-61 Body Mass Index over Time is Associated with Overall Survival in Advanced NSCLC Patients Treated with Immunotherapy.
Authors: S. Labomascus, I. Fughhi, P. Bonomi, A. Mcdonald, M. Batus, M.J. Fidler, S. Basu, J. Borgia
Journal: Journal of Thoracic Oncology (2018)
RING observational trial to compare T790M mutation testing in blood by different methodologies
Authors: B. Garcia-Pelaez, E. Jantus, A. Romero, M.-A. Molina, A. Blasco Cordellat, C. Perez-Barrios, R. Rosell, C. Camps, M. Provencio Pulla
Journal: Annals of Oncology (2018)
Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency
Authors: Paola Bianchi, Elisa Fermo, Bertil Glader, Hitoshi Kanno, Archana Agarwal, Wilma Barcellini, Stefan Eber, James D. Hoyer, David J. Kuter, Tabita Magalhães Maia, Maria del Mar Mañu‐Pereira, Theodosia A. Kalfa, Serge Pissard, José‐Carlos Segovia, Eduard van Beers, Patrick G. Gallagher, David C. Rees, Richard van Wijk
Journal: American Journal of Hematology (2018)

Pyruvate kinase deficiency (PKD) is the most common enzyme defect of glycolysis and an important cause of hereditary, nonspherocytic hemolytic anemia. The disease has a worldwide geographical distribution but there are no verified data regarding its frequency. Difficulties in the diagnostic workflow and interpretation of PK enzyme assay likely play a role. By the creation of a global PKD International Working Group in 2016, involving 24 experts from 20 Centers of Expertise we studied the current gaps in the diagnosis of PKD in order to establish diagnostic guidelines. By means of a detailed survey and subsequent discussions, multiple aspects of the diagnosis of PKD were evaluated and discussed by members of Expert Centers from Europe, USA, and Asia directly involved in diagnosis. Broad consensus was reached among the Centers on many clinical and technical aspects of the diagnosis of PKD. The results of this study are here presented as recommendations for the diagnosis of PKD and used to prepare a diagnostic algorithm. This information might be helpful for other Centers to deliver timely and appropriate diagnosis and to increase awareness in PKD.
P2.01-111 Clinical Features and Prognosis of Eighty-Five Patients with Primary Pulmonary Lymphoepithelioma-Like Carcinoma
Authors: Q. Yin, G. Gao, C. Zhou, Y. Liu, X. Xie, X. Lin, Z. Zhu, Z. Xie, J. Zhang, O. Ming, R. Chen, S. Li
Journal: Journal of Thoracic Oncology (2018)
MA21.06 Proteins Associated with Survival Differ Depending on Molecular Subtypes, and Mutational- and Smoking-Status In NSCLC Biopsies
Authors: A. Halvorsen, M. Haugen, Å. Øjlert, S. Solberg, L. Jørgensen, G. Mælandsmo, O. Brustugun, Å. Helland
Journal: Journal of Thoracic Oncology (2018)
Abstract 2711: Analysis of the Mechanisms Initiating Random Wave Propagation at the Onset of Atrial Fibrillation Using the Non-contact Mapping System: Role of Complex Fractionated Electrogram Region
Authors: Hiroshige Yamabe, Yasuaki Tanaka, Kenji Morihisa, Takashi Uemura, Koji Enomoto, Hisao Ogawa
Journal: Circulation (2009)

Background: The precise mechanisms initiating random reentry in atrial fibrillation (AF) has not been well clarified. Objectives: The purpose of this study was to examine the mechanisms of the init...